American Academy of Dermatology Awards Podium Presentation to Phio Pharmaceutical's Clinical Research at 2025 Annual Meeting
Interim Results from clinical study for cutaneous carcinomas presented at Late-Breaking Research SessionMarlborough, Massachusetts--(Newsfile ...
NeuroOne® Accelerates Timeline of 510(k) Submission to FDA for the OneRF® Trigeminal Nerve Ablation System to Treat Facial Pain
Submission for New Intended Use That Leverages Company’s Patented OneRF® Technology Platform Expected in May 2025 EDEN PRAIRIE, Minn., March 11, ...
pharmaphorum6d
Challenges and opportunities in global clinical trials
faster timelines, and increased patient populations. In particular, global clinical trials can potentially lead to simultaneous launches of new medical products in multiple regions across the ...
pharmaphorum5d
The changing environment for pharma and medtech companies in Europe
The EU clinical trials law is currently up for revision ... via EU portal • Risk-based assessment approach • Clear timelines with tacit approval mechanisms (if authorities have not reacted ...
Syntec Optics Enables Revolutionary Photonic Biosensing For Accelerated Drug Discovery
Syntec Optics is providing critical optical manufacturing and sub-assembly processes to image laser light into our OEM's photonic integrated circuits (PICs), enabling the integration of photonic ...
Trump Administration Highlights: Schumer Says Enough Democrats Will Vote to Avert Government Shutdown
Senator Chuck Schumer of New York, the Democratic leader, broke with his party on Thursday and said he would vote for a ...
The Manila Times6d
BioNTech Announces Fourth Quarter and Full Year 2024 Financial Results and Corporate Update
The full audited consolidated financial statements as of and for the year ended December 31, 2024, can be found in BioNTech's Annual Report on Form 20-F filed today with the United States Securities ...
Sagimet Biosciences Inc.: Sagimet Biosciences Announces Clearance of IND for FASN Inhibitor TVB-3567, to be Developed for the Treatment of Acne
TVB-3567 is the Company's second fatty acid synthase (FASN) inhibitor First-in-human Phase 1 trial initiation planned in 2025 SAN MATEO, Calif., March 11, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences ...
ProQR Therapeutics N.V.: ProQR Announces Year End 2024 Operating and Financial Results
Axiomer ADAR-mediated RNA editing pipeline advancing across liver and CNS programs, with CTA filing on track for Q2 2025 for lead program AX-0810 targeting NTCP for Cholestatic diseases Company expect ...
Taiwan News6d
Prelude Therapeutics Reports Full Year 2024 Financial Results and Provides Program Outlook for 2025
WILMINGTON, Del., March 10, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today reported its financial results for the full ...
Business Wire5d
Geron Announces European Commission Approval of RYTELO® (imetelstat), a First-in-Class Telomerase Inhibitor, for the Treatment of Adults With Transfusion-Dependent Anemia Due ...
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today an ...
Taiwan News5d
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2024 Financial Results
Xilio expects to report updated data from the Phase 2 clinical trial in the middle of 2025, including additional response assessments and follow-up. In addition, Xilio continues to enroll patients in ...